LakeShore Biopharma Co., Ltd

LSBNASDAQHealthcare

$0.63

+$0.00(+0.00%)

Market Cap$25840359

P/E Ratio—

52W High$8.6

52W Low$0.574

Avg Volume348K

Open$0.79

Beta0.57

Free Cash Flow Financials Revenue

LakeShore Biopharma Co., Ltd (LSB) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LSB · free cash flow · updated Jun 9, 2026

Core FCF metrics

LSB · FCF · TTM · margin & CAGR

Free cash flow was −$138.8M for FY2025 (fiscal year ending 2025-03-31), up 59.1% year-over-year The FCF margin was -22.6%.

FY2025 Free Cash Flow−$138.8M▲ +59.1% YoY

Trailing 12M (TTM)$0trailing 4 quarters sum

FCF Margin-22.6%−$138.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LSB · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$121.0M(18M)−$138.8M▲ +59.1%-22.6%

FY2024−$295.2M(44M)−$339.5M▼ 41.7%-59.2%

FY2023−$182.5M(57M)−$239.5M▲ +20.0%-34.9%

FY2022−$173.5M(299M)−$299.5M▲ +14.8%-59.6%

FY2021−$246.6M(105M)−$351.5M—-136.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LSB · P/FCF · FCF yield · FCF per share

LakeShore Biopharma Co., Ltd (LSB) reported negative free cash flow of −$0.14B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-03-31

Cash flow statement summary

LSB · cash flow statement · operating / investing / financing

For FY2025, LakeShore Biopharma Co., Ltd generated −$121.0M in operating cash flow and spent 18M in capital expenditures, yielding −$138.8M in free cash flow.

Operating Activities

−$121.0M

Cash from core business operations

2025-03-31

Investing Activities

−$17.0M

CapEx, acquisitions & investments

2025-03-31

Financing Activities

−$3.6M

Buybacks, dividends & debt

2025-03-31

FCF FormulaOperating CF (−$121.0M) − |CapEx| (18M) = FCF (−$138.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LSB vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

LakeShore Biopharma Co., LtdYOU

LSB

−$138.8M+59.1%-22.6%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

LakeShore Biopharma Co., Ltd (LSB) reported free cash flow of −$138.8M for FY2025 (fiscal year ending 2025-03-31), up 59.1% year-over-year. The FCF margin was -22.6%.

LakeShore Biopharma Co., Ltd has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 5 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LSB free cash flow · 8 questions

LakeShore Biopharma Co., Ltd free cash flow was −$138.8M for FY2025, up 59.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $0.

LSB free cash flowLSB FCFLSB FCF 2025LSB free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · LakeShore Biopharma Co., Ltd · LakeShore Biopharma Co., Ltd SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026